Lung cancer is the primary cause of mortality in the United States and around the globe.
Therapeutic options for lung cancer treatment include surgery, radiation therapy …

Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity.
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …

Small-cell lung cancer (SCLC) represents about 15% of all lung cancers and is marked by
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …

The classification of neuroendocrine neoplasms (NENs) differs between organ systems and
currently causes considerable confusion. A uniform classification framework for NENs at any …

This review summarizes key recent developments relevant to the pathologic diagnosis of
lung neuroendocrine neoplasms, including carcinoids, small cell lung carcinoma (SCLC) …

Since the 2015 WHO classification was introduced into clinical practice,
immunohistochemistry (IHC) has figured prominently in lung cancer diagnosis. In addition to …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung
Cancer (SCLC) provide recommended management for patients with SCLC, including …

The NCCN Guidelines for Small Cell Lung Cancer (SCLC) address all aspects of disease
management. These NCCN Guidelines Insights focus on recent updates to the NCCN …

The incidence and mortality of small-cell lung cancer worldwide make this disease a notable
health-care issue. Diagnosis relies on histology, with the use of immunohistochemical …

Simple Summary Small cell lung carcinoma (SCLC), is a high-grade neuroendocrine
carcinoma defined by its aggressiveness, poor differentiation, and somber prognosis. This …